| abstract |
A BCMA-specific fibronectin type III (FN3) domain, a BCMA targeted chimeric antigen receptor (CAR) having an FN3 domain, and a genetically engineered BCMA targeted immune cell expressing CAR are described. Also described are compositions comprising nucleic acids and expression vectors encoding FN3 domains and CAR, recombinant cells containing the vectors, and genetically engineered immune cells. Also described are methods of making FN3 domains, CAR, and genetically engineered immune cells, and methods of using genetically engineered immune cells to treat diseases including cancer. |